Aeglea BioTherapeutics announces new positive interim clinical data
Aeglea BioTherapeutics announced new positive interim clinical data from its ongoing Phase 1/2 trial of pegzilarginase, its lead investigational therapy, in patients with the rare genetic disease Arginase 1 Deficiency (ARG1-D). October 17, 2018